Drug intelligence / Profile preview

Yishen Huazhuo Granules

Development stage: Unknown
Lead developer: Tianjin Institute of Pharmaceutical Research
Administration: Oral

Overview

Yishen Huazhuo Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Tianjin Institute of Pharmaceutical Research for the treatment of chronic kidney diseases, specifically membranous nephropathy and IgA nephropathy. It is indicated for patients presenting with the TCM syndrome of spleen and kidney qi deficiency and blood stasis. The drug aims to reduce proteinuria and stabilize renal function by addressing underlying systemic imbalances according to TCM principles. It has been evaluated in Phase 2 clinical trials in China to determine the optimal dosage and safety profile for treating primary glomerular diseases.

Brand names: Yishen Huazhuo Granules
Other names: 益肾化浊颗粒

Targets

TREM2 (Triggering receptor expressed on myeloid cells 2)

Beyond the preview

Go deeper on Yishen Huazhuo Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yishen Huazhuo Granules.

Explore the full profile